0001493152-20-012555.txt : 20200702
0001493152-20-012555.hdr.sgml : 20200702
20200702171706
ACCESSION NUMBER: 0001493152-20-012555
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200701
FILED AS OF DATE: 20200702
DATE AS OF CHANGE: 20200702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Diaz-Mitoma Francisco
CENTRAL INDEX KEY: 0001701865
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37769
FILM NUMBER: 201010823
MAIL ADDRESS:
STREET 1: 222 THIRD STREET, SUITE 2241
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VBI Vaccines Inc/BC
CENTRAL INDEX KEY: 0000764195
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 THIRD STREET
STREET 2: SUITE 2241
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-830-3031
MAIL ADDRESS:
STREET 1: 222 THIRD STREET
STREET 2: SUITE 2241
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: SciVac Therapeutics Inc.
DATE OF NAME CHANGE: 20150717
FORMER COMPANY:
FORMER CONFORMED NAME: LEVON RESOURCES LTD.
DATE OF NAME CHANGE: 20100910
FORMER COMPANY:
FORMER CONFORMED NAME: LEVON RESOURCES LTD
DATE OF NAME CHANGE: 19850305
4
1
ownership.xml
X0306
4
2020-07-01
0
0000764195
VBI Vaccines Inc/BC
VBIV
0001701865
Diaz-Mitoma Francisco
C/O VBI VACCINES INC.,
222 THIRD STREET, STE 2241
CAMBRIDGE
MA
02142
0
1
0
0
Chief Medical Officer
Option (Right to Buy Common Shares)
2.99
2020-07-01
4
A
0
167150
0
A
2030-07-01
Common Shares
167150
167150
D
Exercise price represents the volume weighted average closing price of the Issuer's common shares on the Nasdaq Capital Market for Grant Date (as defined below) and the four (4) trading days preceding the Grant Date.
The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on July 1, 2020 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated July 1, 2020 (the "Option Agreement"). 25% of the options vest and become exercisable on the one-year anniversary of the Grant Date, with the remaining 75% of the options vesting and becoming exercisable in 24 equal monthly installments beginning on the first day of the month following the one-year anniversary of the Grant Date, subject to the reporting person's employment on the relevant vesting date.
The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement.
/s/ Francisco Diaz-Mitoma
2020-07-02